{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:50:03Z","timestamp":1788537003350,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Based on previous studies in the sepsis population, Vitamin C could prevent injuries when administered in high doses and before the damage is established. This study aimed to evaluate the protective potentials of high-dose Vitamin C in the progression of coronavirus disease 2019 (COVID-19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A double-blind, placebo-controlled clinical trial was conducted. Patients with moderate-to-severe disease severity based on the World Health Organization definition were enrolled and received 12 g\/d Vitamin C (high-dose intravenous Vitamin C [HDIVC]) or placebo for 4 days. Sequential Organ Failure Assessment (SOFA) score as a primary outcome, National Early Warning Score, Ordinal Scale of Clinical Improvement, and cytokine storm biomarkers were recorded on days 0, 3, and 5. Survival was also assessed on day 28 after enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>\n                      Seventy-four patients (37 patients in each group) were enrolled from April 5, 2020, to November 19, 2020, and all patients completed follow-up. A lower increase in SOFA score during the first 3 days of treatment (+0.026 vs. +0.204) and a higher decrease in this parameter in the last 2 days (\u22120.462 vs. \u22120.036) were observed in the treatment group. However, these differences did not reach a significance level (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.57 and 0.12, respectively). Other indices of clinical and biological improvement, length of hospitalization, and intensive care unit admission days were the same between the two groups. Treatment did not affect the 28-day mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Among patients with moderate-to-severe disease of COVID-19, the use of HDIVC plus standard care resulted in no significant difference in SOFA score or 28-day mortality compared to the standard care alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_30_22","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T09:17:26Z","timestamp":1670923046000},"page":"64-72","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["High-dose Intravenous Vitamin C in Early Stages of Severe Acute Respiratory Syndrome Coronavirus 2 Infection"],"prefix":"10.4103","volume":"11","author":[{"given":"Zohre","family":"Labbani-Motlagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahideh","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Aliannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Shafiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Heshmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamadreza","family":"Jafary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Talaschian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Akhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmadreza","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourosh","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20240907","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13613-020-00792-3","article-title":"Pilot trial of high-dose vitamin C in critically ill COVID-19 patients","volume":"11","author":"Zhang","year":"2021","journal-title":"Ann Intensive Care"},{"key":"R2-3-20240907","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect"},{"key":"R3-3-20240907","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s00134-020-06192-2","article-title":"Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS","volume":"46","author":"Ferrando","year":"2020","journal-title":"Intensive Care Med"},{"key":"R5-3-20240907","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"R6-3-20240907","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s43440-020-00176-1","article-title":"Overview of the possible role of vitamin C in management of COVID-19","volume":"72","author":"Abobaker","year":"2020","journal-title":"Pharmacol Rep"},{"key":"R7-3-20240907","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s11845-020-02394-1","article-title":"Early use of high-dose vitamin C is beneficial in treatment of sepsis","volume":"190","author":"Lv","year":"2021","journal-title":"Ir J Med Sci"},{"key":"R8-3-20240907","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14336\/AD.2020.0918","article-title":"Low level of Vitamin C and dysregulation of Vitamin C transporter might be involved in the severity of COVID-19 Infection","volume":"12","author":"Patterson","year":"2021","journal-title":"Aging Dis"},{"key":"R9-3-20240907","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13054-020-02880-z","article-title":"COVID-19 pneumonia: ARDS or not?","volume":"24","author":"Gattinoni","year":"2020","journal-title":"Crit Care"},{"key":"R10-3-20240907","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"key":"R11-3-20240907","doi-asserted-by":"crossref","first-page":"100028S","DOI":"10.1016\/j.medidd.2020.100028","article-title":"Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?","volume":"5","author":"Cheng","year":"2020","journal-title":"Med Drug Discov"},{"key":"R12-3-20240907","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/CCM.0b013e3182120cb8","article-title":"Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury","volume":"39","author":"Fisher","year":"2011","journal-title":"Crit Care Med"},{"key":"R13-3-20240907","doi-asserted-by":"crossref","first-page":"L20","DOI":"10.1152\/ajplung.00300.2011","article-title":"Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid","volume":"303","author":"Fisher","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R14-3-20240907","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-12-32","article-title":"Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis","volume":"12","author":"Fowler","year":"2014","journal-title":"J Transl Med"},{"key":"R15-3-20240907","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.11825","article-title":"Effect of vitamin c infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: The CITRIS-ALI randomized clinical trial","volume":"322","author":"Fowler","year":"2019","journal-title":"JAMA"},{"key":"R16-3-20240907","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40001-021-00490-1","article-title":"Safety and effectiveness of high-dose vitamin C in patients with COVID-19: A randomized open-label clinical trial","volume":"26","author":"JamaliMoghadamSiahkali","year":"2021","journal-title":"Eur J Med Res"},{"key":"R17-3-20240907","doi-asserted-by":"crossref","first-page":"674681","DOI":"10.3389\/fimmu.2021.674681","article-title":"Vitamin C may increase the recovery rate of outpatient cases of SARS-CoV-2 infection by 70%: Reanalysis of the COVID A to Z randomized clinical trial","volume":"12","author":"Hemil\u00e4","year":"2021","journal-title":"Front Immunol"},{"key":"R18-3-20240907","first-page":"180","article-title":"Stability of intravenous vitamin C solutions: A technical report","volume":"20","author":"Carr","year":"2018","journal-title":"Crit Care Resusc"},{"key":"R19-3-20240907","doi-asserted-by":"crossref","first-page":"E1994","DOI":"10.3390\/nu11091994","article-title":"Administration of intravenous ascorbic acid-practical considerations for clinicians","volume":"11","author":"Walker","year":"2019","journal-title":"Nutrients"},{"key":"R20-3-20240907","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1749-6632.1975.tb29311.x","article-title":"Safety considerations with high ascorbic acid dosage","volume":"258","author":"Barness","year":"1975","journal-title":"Ann N Y Acad Sci"},{"key":"R21-3-20240907","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/annonc\/mdn377","article-title":"Phase I clinical trial of i.v. ascorbic acid in advanced malignancy","volume":"19","author":"Hoffer","year":"2008","journal-title":"Ann Oncol"},{"key":"R22-3-20240907","doi-asserted-by":"crossref","first-page":"2488.e3","DOI":"10.1016\/j.ajem.2020.05.099","article-title":"High dose vitamin C induced methemoglobinemia and hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency","volume":"38","author":"Lo","year":"2020","journal-title":"Am J Emerg Med"},{"key":"R23-3-20240907","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.metabol.2008.09.023","article-title":"Oxalic acid excretion after intravenous ascorbic acid administration","volume":"58","author":"Robitaille","year":"2009","journal-title":"Metabolism"},{"key":"R25-3-20240907","doi-asserted-by":"crossref","first-page":"2001494","DOI":"10.1183\/13993003.01494-2020","article-title":"The Post-COVID-19 Functional Status scale: A tool to measure functional status over time after COVID-19","volume":"56","author":"Klok","year":"2020","journal-title":"Eur Respir J"},{"key":"R26-3-20240907","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"R27-3-20240907","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/nu13041172","article-title":"Vitamin C in the treatment of COVID-19","volume":"13","author":"Milani","year":"2021","journal-title":"Nutrients"},{"key":"R28-3-20240907","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jama.2019.11643","article-title":"Is high-dose vitamin C beneficial for patients with sepsis?","volume":"322","author":"Brant","year":"2019","journal-title":"JAMA"},{"key":"R29-3-20240907","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13613-019-0532-9","article-title":"Effects of different ascorbic acid doses on the mortality of critically ill patients: A meta-analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Ann Intensive Care"},{"key":"R30-3-20240907","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1186\/s12879-021-06288-0","article-title":"Effect of Vitamin C on mortality of critically ill patients with severe pneumonia in intensive care unit: A preliminary study","volume":"21","author":"Mahmoodpoor","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R31-3-20240907","first-page":"7020","article-title":"The efficiency and safety of high-dose vitamin C in patients with COVID-19: A retrospective cohort study","volume":"13","author":"Gao","year":"2021","journal-title":"Aging (Albany NY"},{"key":"R32-3-20240907","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-140-7-200404060-00010","article-title":"Vitamin C pharmacokinetics: Implications for oral and intravenous use","volume":"140","author":"Padayatty","year":"2004","journal-title":"Ann Intern Med"},{"key":"R33-3-20240907","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chest.2018.02.025","article-title":"Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens","volume":"153","author":"de Grooth","year":"2018","journal-title":"Chest"},{"key":"R34-3-20240907","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/014107680710001109","article-title":"Vitamin C may affect lung infections","volume":"100","author":"Hemil\u00e4","year":"2007","journal-title":"J R Soc Med"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_30_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:25:09Z","timestamp":1787757909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_30_22"}},"subtitle":["A Double-blind, Randomized, Controlled Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_30_22","relation":{},"ISSN":["2319-9644"],"issn-type":[{"value":"2319-9644","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}